https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Riliprubart Receives FDA Orphan Drug Designation for AMR in Solid Organ Transplantation

Riliprubart Receives FDA Orphan Drug Designation for AMR in Solid Organ Transplantation

This designation is significant because there are no FDA-approved treatments for transplant recipients with or preventing antibody-mediated rejection (AMR).

administrator

Related Articles